Clinical trials

Human brain
#Biologics / Biotechnology #Clinical trials #Drug discovery #Neurology

Calidi Biotherapeutics gets FDA go-ahead for US trial  

Biotechnology company Calidi Biotherapeutics has announced that a Phase I US clinical trial will use the company’s licensed oncolytic virotherapy platform NeuroNova to deliver an oncolytic adenovirus selectively to tumor sites in patients with recurrent high-grade glioma.  The phase I physician-sponsored clinical trial will take place at… Read More

#News

Clinical trial
#Clinical trials #Drug development #Podcast

Latest DDW Podcast: Transforming clinical trials

This is the latest episode of the free DDW podcast, “Now is the time for the transformation of clinical trials”. It covers two narrated articles written for Volume 22, Issue 4 – Fall 2021 of DDW. They are called “Clinical trials, the pandemic and technology” and “Pharma and the… Read More

#News

Clinical trial
#Clinical trials #Drug development #Narrated podcasts

Now is the time for the transformation of clinical trials

This is the latest episode of the free narrated DDW podcast, “Now is the time for the transformation of clinical trials”. It covers two narrated articles written for Volume 22, Issue 4 – Fall 2021 of DDW. They are called “Clinical trials, the pandemic and technology” and… Read More

#Podcasts

#Cell and gene therapy #Clinical trials #Oncology

Sitting down with Calidi Biotherapeutics

Listen to this article on the DDW Podcast: Dr Boris Minev, President of Medical and Scientific Affairs at Calidi Biotherapeutics speaks to DDW’s Reece Armstrong about the company’s approach to treating cancer. RA: Could you give us an idea of your current pipeline? BM: Calidi Biotherapeutics’ current pipeline consists of oncolytic… Read More

#Exclusive Content

#Biotechnology #Clinical trials #Innovate UK #Psychedelics

Awakn Life Sciences receives UK backing for ketamine therapy  

Biotechnology company Awakn Life Sciences has received funding from Innovate UK to help it advance its ketamine-assisted therapy programme to market in the UK and US.   Awakn Life Sciences has developed a ketamine-assisted therapy programme for treating alcohol use disorder (AUD). The company plans to work with… Read More

#News

Haemophilia
#Clinical trials #Novo Nordisk

Novo Nordisk announces positive results for haemophilia treatment  

Pharmaceutical company Novo Nordisk has announced positive results for its prophylactic treatment targeting people living with haemophilia A or B with inhibitors.   The company’s concizumab treatment is an anti-tissue factor pathway inhibitor (TFPI) antibody in development to prevent prolonged and spontaneous bleeding in all types of… Read More

#News

#Clinical trials #Deep learning #Start-ups

Global pharma start-up success stories

Listen to this article on the DDW Podcast: From AI to 3D deep-learning research to biologics, Lu Rahman selects some interesting global start-ups pushing the boundaries in drug discovery. Owkin French-American startup, Owkin is focussed on using artificial intelligence (AI) to discover and develop better treatments for unmet medical needs, starting… Read More

#Exclusive Content #Start-up Zone

#Clinical trials #Digital #Regulatory

Veeva R&D Summit streamlines drug development  

The Veeva R&D and Quality Summit Europe gathered over 500 life sciences leaders in Zurich to explore new approaches for advancing digital trials and improving the clinical, quality, regulatory, and safety processes throughout.   The Summit, which took place at the start of June saw attendees learn… Read More

#News

#AI / data analytics / healthtech / informatics #Clinical trials #Psychedelics

Beckley Psytech partners with Ksana Health to boost clinical trial data  

Clinical stage company Beckley Psytech has partnered with behavioural health company Ksana Health to use the company’s technology to support its future clinical trials.  Beckley Psytech will use Ksana Health’s Effortless Assessment Research System (EARS) to collect passive mobile device meta data from clinical trial participant’s smartphones. Read More

#News

#Clinical trials #CRO

Celerion takes industry award for seventh year running  

Clinical research organisation (CRO) Celerion has been recognised for its contributions to the industry by claiming an award for the seventh consecutive year.   The company was named  recipient of the Life Science Leader and Clinical Leader’s CRO Leadership Awards in all five award categories. The awards recognise… Read More

#News

#Clinical trials #Diversity #Pharmaceutical #Pharmaceutical research #Rare disease

The company bringing patients to clinical trials  

DDW’s Reece Armstrong speaks to Scott Gray, President & CEO of Clincierge about its unique approach to improving the clinical trial experience for patients.   For patients participating in a clinical trial, the experience can be one of considerable hardship, both from a perspective on their health and the impact on… Read More

#Exclusive Content #Opinion

#AI / data analytics / healthtech / informatics #Clinical trials #Digital twin

Phesi launches digital twin to assist CAR-T development  

Artificial intelligence (AI) solutions provider Phesi has developed a digital twin for Cytokine Release Syndrome (CRS) patients following CAR-T therapy.  Phesi has developed the digital twin for CRS in order to support the development of new CAR-T therapies for the treatment of different types of cancer.   … Read More

#News

#Clinical development #Clinical trials #Manufacturing

SMC opens new pharma business in Cambridge  

Solutions provider SMC Ltd has opened a new business offering pharmaceutical development services at the Cambridge Research Park in the UK.  Cambridge Pharma offers pharmaceutical development services, including sterile fill-finish and launches with a 20,000 sq. ft facility offering a range of manufacturing services for clinical trial… Read More

#News

#AstraZeneca #Clinical trials #Monoclonal antibodies

First patients dosed in trial for AstraZeneca’s Lupus treatment  

The first patients have been dosed in a Phase III clinical trial testing AstraZeneca’s treatment for lupus nephritis (LN).   The IRIS Phase III trial will be conducted in multiple countries across two years and is expected to enrol up to 360 participants aged between 18 and 70. Read More

#News

#Clinical trials #Leukaemia #Oncology

Nurix expands protein degrader into CLL   

Biopharmaceutical company Nurix Therapeutics has initiated the first of several potential Phase 1b expansion cohorts in its ongoing Phase 1 trial of its lead drug candidate targeting relapsed or refractory B-cell malignancies  The company’s lead candidate, NX-2127, is an orally administered degrader of Bruton’s tyrosine kinase (BTK)… Read More

#News

EBV virus
#Clinical trials #Epstein-Barr virus

US launches Epstein-Barr virus trial  

The National Institute of Allergy and Infectious Diseases (NIAID) has launched a clinical trial to evaluate an investigational preventative vaccine for Epstein-Barr virus (EBV). Part of the National Institutes of Health, NIAID will conduct a Phase 1 study at the NIH Clinical Center in Bethesda, Maryland to evaluate the… Read More

#News